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Introduction – Tyrosinase is a multifunctional copper-containing oxidase enzyme that 23 
catalyzes the first steps in the formation of melanin pigments. Identification of tyrosinase 24 
inhibitors is of value for applications in cosmetics, medicine and agriculture. 25 
Objective – To develop an analytical method that allows identification of drug-like natural 26 
products that can be further developed as tyrosinase inhibitors. Results of in vitro and in silico 27 
studies will be compared in order to gain a deeper insight into the mechanism of action of 28 
enzyme inhibition. 29 
Method – Using an in vitro assay we tested tyrosinase inhibitor effects of five structurally 30 
related flavones, i.e. luteolin (1), eupafolin (2), genkwanin (3), nobiletin (4), and 31 
chrysosplenetin (5). The strongest inhibitors were further investigated in silico, using enzyme 32 
docking simulations. 33 
Results - All compounds tested showed modest tyrosinase inhibitory effect compared to the 34 
positive control, kojic acid. The polymethoxy flavones 4 and 5 exhibited the strongest 35 
tyrosinase inhibitory effect with IC50 values of 131.92 ± 1.75 μM and 99.87 ± 2.38 μM 36 
respectively. According to kinetic analysis 2, 4 and 5 were competitive inhibitors, whereas 1 37 
and 3 were noncompetitive inhibitors of tyrosinase. Docking studies indicated that methoxy 38 
groups on 4 and 5 caused steric hindrance which prevented alternative binding modes in the 39 
tyrosinase; the methoxy groups on the B-ring of these flavones faced the catalytic site in the 40 
enzyme. 41 
Conclusions – The docking simulations nicely complemented the in vitro kinetic studies, 42 
opening the way for the development of predictive models for use in drug design. 43 
 44 
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1. INTRODUCTION 47 
Tyrosinase is a multifunctional copper-containing oxidase enzyme that is pivotal for the 48 
production of melanin pigments in bacteria, fungi, plants, and mammals (Chen et al., 2016; 49 
Gou et al., 2017). It acts by catalyzing the oxidation of monophenols to diphenols, and 50 
subsequently to quinones. This process is followed by polymerization of quinones to melanin 51 
pigments (Larik et al., 2017). Melanins protect the skin from damage triggered by UV 52 
absorbed from sunlight and remove reactive oxygen species (ROS). However, overproduction 53 
of melanin leads to its accumulation in the skin causing dermatological conditions such as 54 
freckles, melasma, age spots, and melanoma (Haldys et al., 2018). More seriously, tyrosinase-55 
catalyzed oxidation of dopamine to dopamine quinone derivatives is thought to be a key step 56 
in the etiology of Parkinson’s disease (Anasuma et al., 2003; Hasegawa et al., 2003; 57 
Hasegawa 2010). Tyrosinase is also responsible for undesirable browning in vegetables and 58 
fruits, causing decrease in nutritional quality and economic loss. Thus, tyrosinase inhibitors 59 
may find applications in various fields, e.g. as cosmetics, as medication and in agriculture. 60 
(Gou et al., 2017; Si et al., 2012).  61 
Previous work showed flavonols to be promising tyrosinase inhibitors (Şöhretoğlu et al., 62 
2018b). Following this lead, we aimed to investigate tyrosinase inhibitory potential of some 63 
flavones possessing methoxy substitution (Fig. 1), and propose a mechanism of action based 64 
on in vitro enzyme kinetics and in silico molecular docking studies. Further, we assessed 65 
druglike properties of the most active two compounds using in silico methods. 66 
 67 
 68 





Figure 1: Structures of the flavones 1 = Luteolin, 2 =  Eupafolin (6-methoxyluteolin, 71 
nepetin), 3 = Genkwanin, 4 = Nobiletin, 5 = Chrysosplenetin 72 
 73 
 74 
2. EXPERIMENTAL 75 
2.1 Materials 76 
Kojic acid (KA), L-3,4-dihydroxyphenylalanine (L-DOPA), and mushroom tyrosinase (E.C. 77 
1.14.18.1) were bought from Sigma-Aldrich (St. Louis, MO). All other chemicals used were 78 
analytical grade. 79 
 80 
2.2 Tyrosinase inhibitory effects 81 
The tyrosinase inhibition assay was done as described previously (Arslan et al., 2018). Kojic 82 
acid (KA) was used as positive control and methanol (1% v/v in 100 mM phosphate buffer, 83 
pH 6.8) as negative control. The reaction mixturescomprising 100 µL phosphate buffer (pH 84 
6.8, 100 mM), 20 µL of tyrosinase (250 U/mL) and 20 µL tested compounds, were incubated 85 




the microplate and incubated for 10 min. The absorbance at 475 nm was measured using 87 
microplate reader (Thermo Scientific, Multiskan Go). The concentrations of the compounds 88 
that caused 50% tyrosinase inhibition (IC50) were calculated using the following formula;  89 
% inhibition: (C-A) / C × 100  90 
Where C is the activity of the enzyme without compound and A is the activity of the enzyme 91 
in the presence of the compound. 92 
 93 
2.3 Tyrosinase inhibition kinetic analysis  94 
The kinetic analysis for the compounds was carried out to evaluate the inhibitory types and 95 
inhibitory constant (Ki) values using Lineweaver-Burk and Dixon plots (Lineweaver and 96 
Burk, 1934; Butterworth, 1972). The kinetic analysis was performed according to the 97 
inhibition assay detailed above.  98 
 99 
2.4 Statistical analysis  100 
All the data were analyzed by GraphPad Prism 5.0. The results were expressed as mean ± 101 
standard deviation (n=3). The differences among the compounds were investigated by one-102 
way analysis of variance (ANOVA) followed by Tukey tests. p < 0.0001 was considered to be 103 
significant. 104 
 105 
2.5 Molecular modelling 106 
The compounds were modelled and optimized using MacroModel (2018-4, Schrödinger, 107 
LLC, New York, NY, 2018) and OPLS_2005 force field parameters (Banks 2005). LigPrep 108 
(2018-4, Schrödinger, LLC, New York, NY, 2018) was used to guess possible tautomeric and 109 
ionization states. The descriptors and properties of the ligands were calculated using QikProp 110 




tyrosinase (PDB ID: 2Y9X (Ismaya 2011]) was downloaded from RCSB Protein Data Bank 112 
(www.rcsb.org) (Berman 2000) and prepared for docking with the Protein Preparation Wizard 113 
(2018-4, Schrödinger, LLC, NY, 2018) (Sastry 2013) of Maestro (2018-4, Schrödinger, LLC, 114 
NY, 2018). In this process, undesired residues were removed and the protons were treated 115 
with Epik (2018-4, Schrödinger, LLC, New York, NY, 2018), water orientations were 116 
sampled and H bonds were assigned by Propka. Receptor grid was generated for the catalytic 117 
site taking the centroid coordinates of the co-crystallized ligand, tropolone. Ligands were 118 
docked to this grid flexibly using Glide (2018-4, Schrödinger, LLC, New York, NY, 2018) at 119 
extra precision mode with 50 runs for each ligand (Friesner 2004, Halgren 2004, Friesner 120 
2006). Docking scores are expressed as XP GScore in kcal/mol. Tropolone was re-docked to 121 
the receptor using Glide with above settings and its binding modes were close to their original 122 
conformations (RMSD: 1.33 Å). 123 
 124 
 125 
3. RESULTS AND DISCUSSION 126 
3.1 Inhibitory effects of the compounds on tyrosinase  127 
The IC50 values of 1-5 are presented in Table 1. KA was used as positive control. Among the 128 
tested flavones, 5 showed the highest inhibitory effect on tyrosinase (IC50: 99.87 ± 2.38 µM), 129 
even though it lacks the B-ring catechol moiety seen in compounds 1 and 2, which is often 130 
associated with strong tyrosinase inhibition (Kim et al., 2006). The three strongest inhibitors 131 
in the current series all have methoxy substituents on the C-3’ in the B-ring which, based on 132 
previous literature, would have been expected to reduce the inhibitory activity (Vaya et al., 133 
2011). Also, presence of a methoxy group at C-6 on ring A, as seen in 2, 4, and 5, does not 134 
reduce the inhibitory activity compared to flavones 1 and 2, which is consistent with 135 




activity (Zheng et al., 2009). If anything, the 6-methoxy group seems to enhance the tyrosine 137 
inhibitory activity since 2 showed much higher inhibition than 1 and the only difference 138 
between the two flavones is the additional methoxy group in the A-ring at C-6 in 2. 139 
In contrast, substitution of the C-7 hydroxy group by a methoxy dramatically decreases the 140 
inhibitory effect; flavone 3 had the highest IC50 of the tested compounds (281.60 ± 2.29 µM). 141 
This confirms the importance of the C-7 hydroxyl of flavonoids which has been reported 142 
before. Docking models suggested two alternative binding modes for polyhydroxy flavones, 143 
i.e. one where the 4’-hydroxyl faces the reactive centre in the tyrosinase and one where the 7-144 
hydroxyl faces the copper ions in the enzyme (Kim et al., 2006; Şöhretoğlu et al., 2018b). 145 
 146 
TABLE 1 Tyrosinase inhibitory effects of the flavones tested 147 
          148 
Compound      IC50 (μM)   149 
Luteolin (1)     265.30 ± 2.90* 150 
Eupafolin (2)     209.21 ± 3.35* 151 
Genkwanin (3)      281.60 ± 2.29* 152 
Nobiletin (4)     131.92 ± 1.75* 153 
Chrysosplenetin (5)     99.87 ± 2.38* 154 
Kojic acid      50.00 ± 0.50   155 
*p < 0.0001 (comparing to kojic acid) 156 
 157 
Further docking studies indicated that the hydroxyl groups of B ring of luteolin interact with 158 
Asn81 and Cys83 of mushroom tyrosinase (Zhang et al. 2017). Small differences in the 159 
structures of compounds can cause significant differences on enzyme inhibitory properties. 160 
However, our data show that the substitution of hydroxyl groups by methoxy groups does not 161 
by default decrease the tyrosinase inhibitory action of flavones. The two strongest inhibitors 162 





3.2 Kinetic analysis of tyrosinase inhibition  165 
The modes of inhibition and Ki values of all the tested compounds on tyrosinase were 166 
determined by Lineweaver-Burk and Dixon plots (Figs. 2 and 3) and are summarized in 167 
Table 2. 168 
 169 
TABLE 2 The results of kinetic studies of tested flavones on tyrosinase 170 
          171 
Compound   Type    Ki (μM)   172 
Luteolin (1)  Non-competitive  130.20 ± 0.22 173 
Eupafolin (2)  Competitive   110.15 ± 0.25 174 
Genkwanin (3)  Non-competitive  130.25 ± 0.53 175 
Nobiletin (4)  Competitive   41.40 ± 0.42 176 
Chrysosplenetin (5) Competitive   14.10 ± 0.20   177 
 178 
The Lineweaver-Burk plots of 2, 4, and 5 (Fig. 2) revealed that the Km values increased with 179 
increasing inhibitor concentration and the Vmax values remained the same, showing that these 180 
compounds inhibited tyrosinase via competitive manner, meaning that they may bind to the 181 
substrate binding site of tyrosinase (Barut et al., 2017). The Ki values of 2, 4 and 5 were 182 
determined to be 110.15 ± 0.25, 41.40 ± 0.42 and 14.10 ± 0.20 µM, respectively (Fig. 3). In 183 
contrast, for 1 and 3 Km values remained the same whilst Vmax diminished with increasing 184 
concentrations of inhibitors and L-DOPA as the substrate (Fig. 2). The results represented that 185 
1 and 3 were noncompetitive inhibitors that might interact with allosteric sites rather than 186 
with the catalytic site of the enzyme. The data were consistent with those reported previously 187 
(Zhang 2017; Lin et al., 2014; Bouzaiene et al., 2016; Zhang et al., 2007). The Dixon plots 188 
showed that the Ki values of 1 and 3 were 130.20 ± 0.22 and 130.25 ± 0.53 µM, respectively 189 





Figure 2: Lineweaver-Burk plots of the 1-5 against tyrosinase enzyme; (A) 1, (B) 2, (C) 3, (D) 192 
4 and (E) 5. 193 
 194 
 195 
3.3 Druglikeness of of 4 and 5 196 
QikProp software is designed to calculate a range of pharmaceutically relevant descriptors of 197 
4 and 5 by comparison with those of the 95% of a dataset of known drug and druglike 198 
compounds. Especially descriptors such as molecular weight, hydrogen bond donor and 199 
acceptor counts, logP, number of rotatable bonds, and total polar surface area are considered 200 





Figure 3: Dixon plots of the 1-5 against tyrosinase enzyme; (A) 1, (B) 2, (C) 3, (D) 4 and (E) 203 
5. 204 
 205 
According to the predicted values, compounds 4 and 5 were expected to have good ADME 206 
(absorption, distribution, metabolism, and excretion) properties.  207 
The QikProp software also allowed predictions on drug metabolism and pharmacokinetic 208 
properties of 4 and 5, based on comparison with those of the 95% of a dataset of known drug 209 
and druglike compounds (data not shown). Preliminary predictions indicate that descriptors of 210 
blood-brain barrier permeability were better for 4, which means that 4 might cross to the 211 





3.4 Molecular docking to mushroom tyrosinase 214 
Tyrosinases occur as tetramers comprising two pairs of identical subunits (H and L) 215 
(Strothkamp 1976). The catalytic subunit, H, includes a binuclear copper-binding site at the 216 
heart of four α-helices. The copper ions are coordinated with three histidine residues each 217 
(His61, His85, His94, and His259, His263, His296). These histidine residues interact with the 218 
nearby residues such as Phe90 and Phe292, thus possess limited side chain flexibility to 219 
maintain the copper-binding site stability (Hazes 1993, Ismaya 2011). His85 is also is 220 
covalently bound to Cys83 with a thioether bond through the side chain. Therefore, an 221 
effective and stable binding to tyrosinase catalytic site requires interactions with the coppers 222 
as well as their histidine ligands and other nearby residues (Ferro 2018), although a number of 223 




Figure 4: The binding mode and interactions of 4 (A and B) and 5 (A and C). 4 is shown as 228 
yellow and 5 as blue sticks, copper ions as orange spheres, and the receptor as color 229 
molecular surface according to the electrostatic potential of the atoms. H bonds are showed 230 





The docking poses of 4 and 5 in the catalytic site were very well superimposed with docking 233 
scores -4.15 and -4.53 kcal/mol, respectively. Compound 5 had a slightly higher predicted 234 
affinity for the active site than 4. Both compared well to kojic acid (-4.80 kcal/mol) which we 235 
reported in our previous study (Şöhretoğlu 2018b). The 4’-methoxy oxygen of the B-ring of 4 236 
and the 4’-hydroxy oxygen of the B-ring of 5 were located roughly 3 Å from one copper and 237 
4.5 Å from the other copper fitting well in this cavity (Figure 4). The chromone rings of both 238 
ligands fit in the narrow neck between Val248 and Phe264 with the methoxy groups 239 
contacting the residues at the entry of the active gorge. The aromatic A-ring of the ligands 240 
failed to show key interactions with the nearby histidine residues although the chromone of 4 241 
made π-π interactions with Phe264, π-cation interactions with Arg268, and H-bonded with 242 
Asn260. Rings B of both compounds were in hydrophobic contacts with His61, His85, and 243 
His263 while ring A H-bonded with His259 (Figure 4). These residues were reported as 244 
catalytic site residues (Ismaya 2011) and cited among other residues to interact with potential 245 
inhibitors (Şöhretoğlu et al., 2018b, Si et al. 2012, Wang et al. 2014, Zhang et al. 2017). The 246 
compounds showed good binding to the active site, but an alternative binding mode, in which 247 
the chromone ring would fit in the cavity near the bi-nuclear copper, was not possible due to 248 
the steric hindrance that would be caused by the bulky methoxy substitutions on the A-ring of 249 
this moiety.  250 
Several flavones and flavonols with a catechol moiety in their B-ring have been shown to be 251 
competitive inhibitors of mushroom tyrosinase (Bouzaiene et al., 2016; Kim et al., 2006; 252 
Şöhretoğlu et al., 2018b; Vaya et al., 2011; Zhang et al., 2007; Zhang et al., 2017). Due to 253 
their structural resemblance, these compounds can displace L-DOPA and their catechol group 254 
then binds with the copper ions in the catalytic domain of tyrosinase (Kubo et al., 2004). In 255 
addition to being inhibitors, the flavone luteolin and the flavonol quercetin are also substrates 256 




Fenoll et al., 2003). The o-quinone products have altered pharmacological properties, e.g. 258 
luteolin o-quinone is an inhibitor of glutathione S-transferase and may be used to combat 259 
GST-induced drug resistance in melanomas (Awad et al., 2002; Balyan et al., 2005; Hayeshi 260 
et al., 2007). However, it is prudent to be cautious. Arguably, rather than inhibiting the 261 
formation of quinones, catechol-type flavones introduce new quinones into the mix, and the 262 
exact consequences are hard to predict. In contrast, methoxy flavones act as competitive 263 
inhibitors of tyrosinase, but are not substrates for the enzyme.  264 
 265 
TABLE 3 Predicted drug-like properties for compounds 4 and 5 266 
          267 
Descriptor  4  5  Recommended  268 
      range or values  269 
Rotatable bonds  6  6   0 to 15 270 
Molecular weight (Da) 402.4  374.3   130 to 725 271 
H-bond donor   0  1   0 to 6 272 
H-bond acceptor  7  6   2 to 20 273 
Log P    3.49  2.94   −2.0 to 6.5 274 
Polar surface  73.67  103.48   7 to 200 275 
area (Å2)         276 
 277 
Whereas methoxy flavones do competitively inhibit tyrosinase, their application in cosmetic 278 
or medicinal products that aim to decrease tyrosine or dopamine oxidation should be treated 279 
with caution. Experiments with murine B16/F10 melanoma cells have shown that treatment 280 
with polyhydroxy flavones results in reduced melanogenesis (Horibe et al., 2013; Kumagai et 281 
al., 2011) but that polymethoxy flavones affect cell signaling, and induce tyrosinase 282 
expression and melanogenesis (Chung et al. 2017; Horibe et al., 2013; Kim et al., 2015b; Ko 283 




experiments with human rather than murine melanocytes have shown that polymethoxy 285 
flavones inhibit the induction of melanogenesis (Kim et al. 2015a). 286 
 287 
3.5 Conclusions 288 
The polymethoxy flavones 4 (nobiletin) and 5 (chrysosplenetin) were the most potent 289 
tyrosinase inhibitors among the tested compounds, though overall the inhibitory activity of 290 
methoxylated flavones was only modest. Enzyme kinetics analyses revealed that 2 291 
(eupafolin), 4, and 5 were competitive tyrosinase inhibitors.  292 
Molecular docking studies demonstrated that the most active compounds can bind to the 293 
catalytic site of tyrosinase with good affinity and interact with key residues, notably with 294 
copper ions, in the enzyme. In terms of druglikeness and pharmacokinetics (Hay 2014), 295 
modelling studies predicted that these flavones should be considered as promising candidates 296 
for further drug development.  297 
 298 
 299 
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